Please wait while the formulary information is being retrieved.
RISPERDAL CONSTA (RISPERIDONE MICROSPHERES)
- Bipolar disorder in remission
- Schizophrenia
12.5 mg/2 mL intramuscular syringe
- Inject 4 milliliters (25 mg) using 2 separate injection sites by intramuscular route every 14 days by deep gluteal injection
25 mg/2 mL intramuscular syringe
- Inject 2 milliliters (25 mg) by intramuscular route by deep gluteal injection repeat every 2 weeks
37.5 mg/2 mL intramuscular syringe
- Inject 2 milliliters (37.5 mg) by intramuscular route by deep glutealinjection repeat every 2 weeks
50 mg/2 mL intramuscular syringe
- Inject 2 milliliters (50 mg) by intramuscular route by deep gluteal injection repeat every 2 weeks
Bipolar disorder in remission
- Inject 2 milliliters (25 mg) by intramuscular route by deep gluteal injection repeat every 2 weeks
- Inject 2 milliliters (25 mg) by intramuscular route by deep gluteal injection
- Inject 4 milliliters (25 mg) using 2 separate injection sites by intramuscular route every 14 days by deep gluteal injection
- Inject 2 milliliters (50 mg) by intramuscular route by deep gluteal injection repeat every 2 weeks
- Inject 2 milliliters (50 mg) by intramuscular route by deep gluteal injection
- Inject 2 milliliters (37.5 mg) by intramuscular route by deep glutealinjection
- Inject 2 milliliters (37.5 mg) by intramuscular route by deep glutealinjection repeat every 2 weeks
Schizophrenia
- Inject 2 milliliters (25 mg) by intramuscular route by deep gluteal injection repeat every 2 weeks
- Inject 2 milliliters (25 mg) by intramuscular route by deep gluteal injection
- Inject 4 milliliters (25 mg) using 2 separate injection sites by intramuscular route every 14 days by deep gluteal injection
- Inject 2 milliliters (50 mg) by intramuscular route by deep gluteal injection repeat every 2 weeks
- Inject 2 milliliters (50 mg) by intramuscular route by deep gluteal injection
- Inject 2 milliliters (37.5 mg) by intramuscular route by deep glutealinjection
- Inject 2 milliliters (37.5 mg) by intramuscular route by deep glutealinjection repeat every 2 weeks
- metoclopramide HCl
- Metozolv Odt
- Reglan
Contraindicated
- cabergoline
Severe
Moderate
- Alagesic Lq
- amobarbital
- Amytal
- Aplenzin
- Apokyn
- apomorphine
- Ascomp With Codeine
- B cplx-C-St.Johnwrt-K.&S.ginsg
- Belladonna-phenobarbital
- Brisdelle
- Bupap
- Buproban
- bupropion HBr
- bupropion HCl
- butabarbital
- Butalbital Compound W/codeine
- Butalbital Compound-codeine
- butalbital-acetaminop-caf-cod
- butalbital-acetaminophen
- butalbital-acetaminophen-caff
- butalbital-aspirin-caffeine
- Butisol
- calcium-mag-B complex-D3-hrb61
- Capacet
- carbamazepine
- Carbatrol
- carbidopa-levodopa
- carbidopa-levodopa-entacapone
- Cerebyx
- codeine-butalbital-ASA-caff
- Cold & Flu Fighter
- Comtan
- Cymbalta
- Dilantin
- Dilantin Extended
- Dilantin Infatabs
- Dilantin Kapseal
- Dilantin-125
- Donnatal
- duloxetine
- entacapone
- enzalutamide
- Epitol
- Equetro
- Esgic
- Fatigue Relief Complex
- Fioricet
- Fioricet With Codeine
- Fiorinal
- Fiorinal-codeine #3
- fluoxetine
- Forfivo Xl
- fosphenytoin
- isoniazid-rifamp-pyrazinamide
- Luminal
- Lysodren
- Margesic
- Marten-tab
- Mirapex
- Mirapex Er
- mitotane
- Mycobutin
- Mysoline
- Nembutal Sodium
- olanzapine-fluoxetine
- paroxetine HCl
- paroxetine mesylate
- Paxil
- Paxil Cr
- pentobarbital sodium
- Pexeva
- phenobarb-hyoscy-atropine-scop
- phenobarbital
- phenobarbital sodium
- Phenytek
- phenytoin
- phenytoin sodium
- phenytoin sodium extended
- pramipexole
- primidone
- Prozac
- Prozac Weekly
- Requip
- Requip Xl
- rifabutin
- Rifadin
- Rifamate
- rifampin
- rifampin-isoniazid
- Rifater
- ropinirole
- Sarafem
- secobarbital sodium
- Seconal Sodium
- Sinemet
- Sinemet Cr
- St. John's wort
- Stalevo 100
- Stalevo 125
- Stalevo 150
- Stalevo 200
- Stalevo 50
- Stalevo 75
- Symbyax
- Tegretol
- Tegretol Xr
- Tencon
- vit C-St. John wort-elder-hb30
- Wellbutrin
- Wellbutrin Sr
- Wellbutrin Xl
- Women's Complex
- Xtandi
- Zebutal
- Zyban
- Agranulocytosis
- Congenital long QT syndrome
- Neuroleptic malignant syndrome
Contraindicated
- Acute myocardial infarction
- Atherosclerotic cardiovascular disease
- Cardiac arrhythmia
- Cataract surgery
- Cerebrovascular accident
- Cerebrovascular disorder
- Chronic heart failure
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Dehydration
- Diffuse lewy body disease
- Disease of liver
- Hypotension
- Hypovolemia
- Leukopenia
- Myocardial ischemia
- Neutropenic disorder
- Orthostatic hypotension
- Parkinsonism
- Rhabdomyolysis
- Senile dementia
- Severe hepatic disease
- Tardive dyskinesia
Severe
Moderate
- Acute confusion
- Carcinoma of breast
- Diabetes mellitus
- Drug abuse
- Dysphagia
- Fever
- Hyperlipidemia
- Hyperprolactinemia
- Hypothermia
- Intraoperative floppy iris syndrome
- Metabolic syndrome X
- Obesity
- Predisposition to aspiration
- Priapism
- Seizure disorder
- Urinary retention
- Weight gain
RISPERDAL CONSTA (RISPERIDONE MICROSPHERES)
- Bipolar disorder in remission
- Schizophrenia
- Acquired dystonia
- Akathisia
- Extrapyramidal disease
- Parkinsonism
- Agitation
- Constipation
- Diarrhea
- Dizziness
- Drowsy
- Dyspepsia
- Fatigue
- Headache disorder
- Increased appetite
- Musculoskeletal pain
- Nasal congestion
- Rhinitis
- Sedation
- Sialorrhea
- Skin rash
- Tremor
- Upper respiratory infection
- Weight gain
- Xerostomia
More Frequent
Severe
Less Severe
- SIADH syndrome
- Tachycardia
- Acne vulgaris
- Cough
- Hyperlipidemia
- Hypertriglyceridemia
- Hypesthesia
- Injection site sequelae
- Insomnia
- Myalgias
- Nausea
- Orthostatic hypotension
- Pain
- Peripheral edema
- Pharyngitis
- Sinusitis
- Sore throat
- Toothache
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Accidental fall
- Agranulocytosis
- Anaphylaxis
- Anemia
- Angioedema
- Atrial fibrillation
- Bundle branch block
- Cerebrovascular accident
- Chest pain
- Depression
- Diabetes mellitus
- DRESS syndrome
- Drug-induced psychosis
- Dyspnea
- Esophageal dysmotility
- Heart block
- Hyperglycemia
- Hypertension
- Hypoglycemic disorder
- Hypokinesia
- Hypotension
- Hypothermia
- Ileus
- Jaundice
- Leukopenia
- Neuroleptic malignant syndrome
- Neutropenic disorder
- Pancreatitis
- Priapism
- Retinal vascular occlusion
- Seizure disorder
- Sinus bradycardia
- Sleep apnea
- Tardive dyskinesia
- Thrombotic thrombocytopenic purpura
- Urinary retention
Less Severe
- Abscess
- Acute abdominal pain
- Alopecia
- Amenorrhea
- Anorexia
- Arthralgias
- Ataxia
- Back pain
- Blurred vision
- Complex sleep behavior
- Conjunctivitis
- Disorder of ejaculation
- Dry skin
- Dysarthria
- Dysgeusia
- Dysphagia
- Earache
- Eczema
- Erectile dysfunction
- Eyelid edema
- Fever
- Flushing
- Gastritis
- General weakness
- Hematoma
- Hyperprolactinemia
- Hypertonia
- Libido changes
- Limb pain
- Mastalgia
- Menstrual disorder
- Muscle weakness
- Neck pain
- Nervousness
- Nightmares
- Palpitations
- Paresthesia
- Pruritus of skin
- Reduced visual acuity
- Rhinorrhea
- Salivary secretion disorder
- Symptoms of anxiety
- Syncope
- Tinnitus
- Urinary incontinence
- Vertigo
- Vomiting
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Risperidone (Inj)
No information on effects of growth and sexual maturation with long term use. Dose form not studied in pediatrics.
- 1 Day – 18 Years
- No information on effects of growth and sexual maturation with long term use. Dose form not studied in pediatrics.
Risperidone Microsph
- Severity Level:
C
- Additional Notes: Non-teratogenic complications (resp, gi,cns) with exposure during 3rd trimester
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Risperidone Microsph (inject)
None
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Risperidone (injection)
Neuro/Psych-Inc risk of tardive dyskinesia. CNS effects; sedation, cognitive impairment, and increased fall risk. Avoid use for behavioral probs of dementia or delirium unless failed nonpharm options. Inc risk of stroke, cognitive decline, and death when used with senile dementia. Endocrine-May exacerbate or cause SIADH or hyponatremia. Cardiovascular-May cause orthostatic hypotension. Gastrointestinal-May cause or worsen constipation. Renal-Titrate carefully w/renal impairment.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | Y | Y | Y | N | Y |
BEERS: Y HEDIS: Y STOPP: Y
No Known Risk
None
- There may be a slightly increased risk of serious, possibly fatal side effects (such as stroke, heart failure, fast/irregular heartbeat, pneumonia) when this medication is used by older adults with dementia. This medication is not approved for the treatment of dementia-related behavior problems. Discuss the risks and benefits of this medication, as well as other effective and possibly safer treatments for dementia-related behavior problems, with the doctor.
| Bipolar disorder in remission | |
| F31.7 | Bipolar disorder, currently in remission |
| F31.70 | Bipolar disorder, currently in remission, most recent episode unspecified |
| F31.71 | Bipolar disorder, in partial remission, most recent episode hypomanic |
| F31.72 | Bipolar disorder, in full remission, most recent episode hypomanic |
| F31.73 | Bipolar disorder, in partial remission, most recent episode manic |
| F31.74 | Bipolar disorder, in full remission, most recent episode manic |
| F31.75 | Bipolar disorder, in partial remission, most recent episode depressed |
| F31.76 | Bipolar disorder, in full remission, most recent episode depressed |
| F31.77 | Bipolar disorder, in partial remission, most recent episode mixed |
| F31.78 | Bipolar disorder, in full remission, most recent episode mixed |
| Schizophrenia | |
| F20 | Schizophrenia |
| F20.0 | Paranoid schizophrenia |
| F20.1 | Disorganized schizophrenia |
| F20.2 | Catatonic schizophrenia |
| F20.3 | Undifferentiated schizophrenia |
| F20.5 | Residual schizophrenia |
| F20.8 | Other schizophrenia |
| F20.81 | Schizophreniform disorder |
| F20.89 | Other schizophrenia |
| F20.9 | Schizophrenia, unspecified |
| 0-9 | A-Z |
|---|---|
| F20 | Schizophrenia |
| F20.0 | Paranoid schizophrenia |
| F20.1 | Disorganized schizophrenia |
| F20.2 | Catatonic schizophrenia |
| F20.3 | Undifferentiated schizophrenia |
| F20.5 | Residual schizophrenia |
| F20.8 | Other schizophrenia |
| F20.81 | Schizophreniform disorder |
| F20.89 | Other schizophrenia |
| F20.9 | Schizophrenia, unspecified |
| F31.7 | Bipolar disorder, currently in remission |
| F31.70 | Bipolar disorder, currently in remission, most recent episode unspecified |
| F31.71 | Bipolar disorder, in partial remission, most recent episode hypomanic |
| F31.72 | Bipolar disorder, in full remission, most recent episode hypomanic |
| F31.73 | Bipolar disorder, in partial remission, most recent episode manic |
| F31.74 | Bipolar disorder, in full remission, most recent episode manic |
| F31.75 | Bipolar disorder, in partial remission, most recent episode depressed |
| F31.76 | Bipolar disorder, in full remission, most recent episode depressed |
| F31.77 | Bipolar disorder, in partial remission, most recent episode mixed |
| F31.78 | Bipolar disorder, in full remission, most recent episode mixed |
Formulary Reference Tool